CLINICAL TRIAL

XOLARIS - NCT03314207

Retinal RED

Observational

Natural history of the progression of X-linked retinitis pigmentosa.

Rare Eye Disease concerned by the trial :
X-linked retinitis pigmentosa with a mutation in RPGR gene

Status of the trial : recruiting

Orphan drug recognition : N/A

Inclusion criteria : Visual Acuity from20/200 to 20/20

Exclusion criteria : Age < 18 years

Inclusion opening date : 01/01/2018

Inclusion closing date (previsional) : 01/01/2020

Children ☐

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Maolya - National Rare Disease center
Centre national de référence affections sensorielles génétiques
CHU Gui de Chauliac
80, avenue Augustin Fliche
34 295 Montpellier Cedex 5

Contact details



Principal investigator name :
Isabelle Meunier

Other investigators :
None

Funder type : Drug company - Industry

More informations

CLINICAL TRIAL

XOLARIS

Retinal RED
Registries

Observational

Multi-centre, prospective, observational study of the Natural History of the Progression of X-Linked Retinitis Pigmentosa

Rare Eye Disease concerned by the trial :
X-linked RP (RPGR)

Status of the trial : recruiting

Orphan drug recognition : N/A

Inclusion criteria : Molecular confirmed mutation in RPGR

Exclusion criteria : Visual Acuity worse than 6/60

Inclusion opening date : 01/11/2017

Inclusion closing date (previsional) : 01/08/2018

Children ☐

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Leeds Teaching Hospital (St.James's Hospital)
Beckett Street
Leeds LS9 7TF
West Yorkshire
UK

Contact details



Principal investigator name :
Kamron Khan

Other investigators :
Robert MacLaren (Chief Investigator)

Oxford Eye Hospital
Level Lg1 John Radcliffe Hospital
Headley Way, Headington
Oxford OX3 9DU
UK

Funder type : Drug company - Industry

More informations

CLINICAL TRIAL

XOLARIS

Research

Observational

Natural History of the Progression of X-Linked Retinitis Pigmentosa

Rare Eye Disease concerned by the trial :
X-Linked Retinitis Pigmentosa

Status of the trial : not yet recruiting

Orphan drug recognition : N/A

Inclusion criteria : Patients are willing and able to provide informed consent for participation in the study, are male ≥16 years of age, have a genetically confirmed diagnosis of XLRP (with retinitis pigmentosa GTPase regulator [RPGR] mutation), have active disease clinically visible within the macular region, are willing and able to undergo ophthalmic examinations once every 3 months for up to 24 months, have an ETDRS BCVA better than or equal to 34 letters in at least one eye.

Exclusion criteria : click here to see detailed criteria

Inclusion opening date : 01/12/2017

Inclusion closing date (previsional) : 01/12/2018

Children ☐

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Center for Opthalmic Research, University Hospital of Tübingen
Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

Contact details

Principal investigator name :
Prof. Dr. Dr. Dominik Fischer

Other investigators :
Prof. Dr. med. Karl Ulrich Bartz-Schmidt

University Hospital of Tübingen
Tübingen, Germany



Funder type : Drug company - Industry

More informations